Date published: 2026-4-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

BoNT/A Antibody (KBA211): sc-51774

2.0(1)
Write a reviewAsk a question

Datasheets
  • BoNT/A Antibody (KBA211) is a mouse monoclonal IgG1 BoNT/A antibody provided at 100 µg/ml
  • raised against full length BoNT/A of Clostridium botulinum origin
  • recommended for detection of BoNT/A of Clostridium botulinum origin by ELISA
  • At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for BoNT/A Antibody (KBA211). This work is in progress.
    Gene Editing Promo Banner

    QUICK LINKS

    SEE ALSO...

    BoNT/A Antibody (KBA211) is a mouse monoclonal IgG1 antibody that detects BoNT/A protein of Clostridium botulinum origin by enzyme-linked immunosorbent assay (ELISA). Anti-BoNT/A antibody (KBA211) is available as the non-conjugated format. Botulinum neurotoxin type A, commonly referred to as BoNT/A, is one of the most potent neurotoxins known, with a mechanism of action critical for understanding both pathogenicity and therapeutic applications. BoNT/A functions as a zinc-dependent endopeptidase that specifically cleaves SNAP-25, a vital protein in the synaptic vesicle release process. By disrupting the exocytotic machinery, BoNT/A effectively inhibits acetylcholine release, leading to flaccid paralysis, which is the hallmark of botulism. The dimeric structure of BoNT/A in aqueous solution is essential for stability and activity, allowing maintenance of toxic effects while being harnessed for therapeutic purposes, such as treating muscle spasms and chronic pain. BoNT/A′s ability to modulate neurotransmitter release has made BoNT/A (KBA211) monoclonal antibody valuable for studying neurotoxin-target interactions.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

    Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA

    LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences

    BoNT/A Antibody (KBA211) References:

    1. Development of vaccines for prevention of botulism.  |  Byrne, MP. and Smith, LA. 2000. Biochimie. 82: 955-66. PMID: 11086225
    2. Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active.  |  Ahmed, SA. and Smith, LA. 2000. J Protein Chem. 19: 475-87. PMID: 11195972
    3. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment.  |  von Lindern, JJ., et al. 2001. Plast Reconstr Surg. 107: 327-32. PMID: 11214045
    4. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A.  |  Keller, JE. and Neale, EA. 2001. J Biol Chem. 276: 13476-82. PMID: 11278807
    5. A correlation between differential structural features and the degree of endopeptidase activity of type A botulinum neurotoxin in aqueous solution.  |  Cai, S. and Singh, BR. 2001. Biochemistry. 40: 4693-702. PMID: 11294637
    6. [Reduction of pain and muscle spasms by botulinum toxin A].  |  Kelm, S., et al. 2001. Nervenarzt. 72: 302-6. PMID: 11320866
    7. A novel neurotoxoid vaccine prevents mucosal botulism.  |  Kobayashi, R., et al. 2005. J Immunol. 174: 2190-5. PMID: 15699151

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    BoNT/A Antibody (KBA211)

    sc-51774
    100 µg/ml
    $322.00